SCHEMBL6554548

SCHEMBL6554548

O=S1(=O)N=C(NC2CCC2)Nc2ccc(F)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC8 Q09428 2/20 0.48
KCNJ11 Q14654 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
TAAR1 Q96RJ0 1/20 0.39
HTR5A P47898 1/20 0.38
CXCR2 P25025 3/20 0.36
JAK2 O60674 2/20 0.36
MAPT P10636 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262374 0.97 ABCC8 (0.45) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL7952015 0.95 CA12 (0.44) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL7950900 0.87 MAPT (0.38) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL7954322 0.85 CA12 (0.43) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL7956791 0.85 CA12 (0.43) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL6555285 0.85 ABCC8 (0.53) ABCC8KCNJ11CA12CA1CA2
SCHEMBL31734775 0.84 L3MBTL1 (0.40) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL24050507 0.82 ABCC8 (0.53) ABCC8KCNJ11CA12CA1CA2
SCHEMBL719284 0.82 CA12 (0.43) ABCC8KCNJ11L3MBTL1CA12CA1
SCHEMBL717798 0.81 ABCC8 (0.52) ABCC8KCNJ11CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0906297-B1 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE UNIV LIEGE (BE) 2004-02-25 EP claimed
US-6242443-B1 1,2,4-benzothiadiazine derivatives, their preparation and use NOVO NORDISK AIS (DK) 2001-06-05 US claimed
CN-1222910-A 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 1999-07-14 CN claimed
US-12209140-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-01-28 US disclosed
US-20230101009-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2023-03-30 US disclosed
US-11505572-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2022-11-22 US disclosed
US-10981951-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-04-20 US disclosed
US-20210040148-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-02-11 US disclosed
US-20170002040-A1 NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-01-05 US disclosed
EP-3099304-A1 NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA Mayo Foundation for Medical Education and Research (US) 2016-12-07 EP disclosed
WO-2015117024-A1 NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2015-08-06 WO disclosed
EP-0906297-B1 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE UNIV LIEGE (BE) 2004-02-25 EP disclosed
US-6242443-B1 1,2,4-benzothiadiazine derivatives, their preparation and use NOVO NORDISK AIS (DK) 2001-06-05 US disclosed
CN-1222910-A 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 1999-07-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101009-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA KCNJ1, KCNJ2, KCNJ11 ABCC8 62/4885KCNJ11 3/4885L3MBTL1 2874/4885
US-20210040148-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA KCNJ1, KCNJ2, KCNJ11 ABCC8 62/4885KCNJ11 3/4885L3MBTL1 2874/4885
US-12209140-B2 Therapeutics for the treatment of glaucoma KCNJ1, KCNJ2, KCNJ11 ABCC8 62/4885KCNJ11 3/4885L3MBTL1 2874/4885
US-20170002040-A1 NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA KCNJ1, KCNK4, KCNK2 ABCC8 67/4885KCNJ11 4/4885L3MBTL1 2509/4885
US-11505572-B2 Therapeutics for the treatment of glaucoma KCNJ1, KCNJ2, KCNJ11 ABCC8 62/4885KCNJ11 3/4885L3MBTL1 2874/4885
US-10981951-B2 Therapeutics for the treatment of glaucoma KCNJ1, KCNJ2, KCNJ11 ABCC8 62/4885KCNJ11 3/4885L3MBTL1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.